Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality

Author(s):  Hagan John C III, Everett Eric, Chamberlain Tyler

Issue:  May/Jun 2020 - Volume 24, Number 3
View All Articles in Issue

Abstract:  Beta blockers (timolol 0.5% ophthalmic solution) delivered topically to the eyes or sublingually have recently been reported in case series and small placebo controlled studies to be effective in some cases of acute migraine. Rapid systemic absorption to achieve therapeutic levels of beta blockers is extremely important in the treatment of acute migraine. Nasal delivered beta blockers have been shown to be absorbed as fast as intravenous administration and seem ideal for acute migraine treatment. A nasal delivered beta-blocker spray has not been available. In 2019, O’Brien Pharmacy prepared a compounded timolol nasal spray that is now available to authorized prescribers. The theoretical basis for using nasal beta blocker spray is presented and research on fast-acting beta-blocker solutions for acute migraine is reviewed.

Related Keywords: John C. Hagan, III, MD, FACS, FAAO, Eric Everett, RPh, Tyler Chamberlain, PharmD, acute migraine, beta-blockers, beta-adrenergic antagonists, timolol eye drops, nasal spray, intranasal administration, formulation, Mucolox gel, beta blockade contraindications

Related Categories: FORMULATIONS, PAIN MANAGEMENT, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version




Download in electronic PDF format for $35

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Hagan John C III, Everett Eric, Chamberlain Tyler May/Jun 2020 194-197 Buy
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Choo Winnie Jul/Aug 2017 282-289 Buy
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE Jul/Aug 2016 328-332 Buy
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Zur Eyal Nov/Dec 2011 458-463 Buy
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A Nov/Dec 2007 520-524 Buy
A Concise Discussion of Headache Types, Part 3: Migraine Williams LaVonn A, Allen Loyd V Jr Jul/Aug 2012 270-274 Buy
Autologous Serum Eye Drops for Severe Dry Eye Syndrome in a Patient with Chronic Graft-vs-Host Disease: A Case Report Mixon Bill, Mixon Jan, Isbey Edward K III, Sprinkle Shari Sep/Oct 2014 370-377 Buy
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H Sep/Oct 2014 418-426 Buy
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis Mixon William, Angelle Patricea (Patsy), Chang Richard I Nov/Dec 2009 506-515 Buy
Compounding with Beta-1, 3-D-Glucan Keller Ted Sep/Oct 2000 342 Buy